US Patent 7598387 Synthesis of antidiabetic rosiglitazone derivatives
Patent 7598387 was granted and assigned to Cipla on October, 2009 by the United States Patent and Trademark Office.
All edits
Edits on 16 Sep, 2023
Golden AI
Edits made to:
Article (+290 characters)
Article
Patent abstract
A process of preparing rosiglitazone, or a pharmaceutically acceptable salt thereof, which process employs an intermediate metabisulphite complex of 4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzaldehyde, which metabisulphite complex is represented by following formula (III):
Edits on 14 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07598387 Synthesis of antidiabetic rosiglitazone derivatives US Patent 7598387 Synthesis of antidiabetic rosiglitazone derivatives
Infobox
Patent Number
0759838700
Patent Number
759838700
Edits on 25 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 3 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
075983870
Date of Patent
October 6, 2009
0Patent Application Number
115686100
Date Filed
May 3, 2005
0Official Website
Patent Primary Examiner
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
075983870
Date of Patent
October 6, 2009
0Patent Application Number
115686100
Date Filed
May 3, 2005
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 3 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07598387 Synthesis of antidiabetic rosiglitazone derivatives
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07598387
Date of patent
October 6, 2009
Patent application number
11568610
Date Filed
May 3, 2005
Patent primary examiner
Find more entities like US Patent 7598387 Synthesis of antidiabetic rosiglitazone derivatives
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
